@thewonkologist.bsky.social
Medical oncologist and health services researcher. Focusing on health care costs, physician-industry COI, and oncology reimbursement reform. Opinions mine.
@thewonkologist.bsky.socialJust finished presenting these new findings at #ASCOQLTY26
Industry payments to oncologists are associated with aggressive end-of-life care for patients with cancer.
@thewonkologist.bsky.socialI'll be presenting our latest this weekend at @ascocancer.bsky.social Quality Care Symposium!
On the association between industry money to oncologists their delivery of lower-quality, more-aggressive end-of-life care
@ryannipp.bsky.social @fumikochino.bsky.social
@thewonkologist.bsky.social“The contrast with financial toxicity is instructive. Financial toxicity, a term coined more than a decade earlier and serving as the explicit template for time toxicity, has never, to our knowledge, been used by a drug company to advertise a LOWER list price for a new drug.” 💯💯💯
@thewonkologist.bsky.socialMust-read perspective in Journal of Clinical Oncology @ascocancer.bsky.social on how the concept of “time toxicity” is being appropriated for industry aims (profits).
I was not aware of this! Eye opening.
@thewonkologist.bsky.socialImages of Freddy Kruger at the video store
@thewonkologist.bsky.social“Patients come to oncology with fear and uncertainty. They are asking for judgment they can trust. That judgment should not be shaped by a meal, an honorarium, or a branded invitation.”
Amazing editorial on our study from @sarojniraula.bsky.social
@thewonkologist.bsky.socialI could not have asked for a better editorial! Thank you for writing this. And for not mincing words. I am in full agreement with your recommendations as well.
@thewonkologist.bsky.social@propublica.org @charlesornstein.bsky.social @medlawdan.bsky.social @profgenkanter.bsky.social @kffhealthnews.org @matthewherper.bsky.social @statnews.com @pharmalot.bsky.social @relentleshealth.bsky.social @armandalegshow.bsky.social @drrobinyabroff.bsky.social @yalecrrit.bsky.social
@thewonkologist.bsky.socialThanks to all my co-authors on this study! @dusetzinas.bsky.social @peterbachmd.bsky.social And to our funders at NCI, @commonwealthfund.org, @arnoldventures.bsky.social, and @nihcm.bsky.social
@thewonkologist.bsky.socialBegs the question - why are we still accepting money and gifts from drug companies?
@thewonkologist.bsky.social...and the AMOUNT of money matters: The more money your oncologists get for the not-as-good drugs (orange), the LESS likely you are to receive treatment with a guideline-preferred drug.
@thewonkologist.bsky.socialOur latest, out today in JCO @ascocancer.bsky.social :
Industry payments to oncologists can sway us to prescribe, regardless of whether the drug is good or bad.
@bradlander.bsky.socialReposted by @thewonkologist.bsky.socialGender-affirming care saves lives, respects the rights of patients, and reflects that healthcare is supposed to be between providers and patients, not between providers and the Trump Administration. (1/3)
@medlawdan.bsky.socialReposted by @thewonkologist.bsky.socialNEW: Draft white paper up on SSRN -
"Reimagining FDA’s Corporate Funding: Pathways to Reform or Abolition of User Fees"
FDA's corporate funding, aka "user fees," are not ancillary -- they have big implications for FDA policy & integrity. (1/x)
